Amicus Therapeutics (FOLD) Rating Reiterated by Cowen

Cowen reiterated their buy rating on shares of Amicus Therapeutics (NASDAQ:FOLD) in a report issued on Wednesday morning. They currently have a $22.00 price target on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued research reports about the company. Leerink Swann reaffirmed a buy rating and set a $20.00 price target (up previously from $17.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Bank of America lifted their price target on Amicus Therapeutics from $15.00 to $20.00 and gave the company a buy rating in a report on Wednesday, October 4th. Chardan Capital reiterated a buy rating and set a $18.50 price objective (up previously from $16.50) on shares of Amicus Therapeutics in a research note on Thursday, October 5th. Zacks Investment Research upgraded shares of Amicus Therapeutics from a hold rating to a buy rating and set a $16.00 price objective on the stock in a research note on Tuesday, October 10th. Finally, BidaskClub upgraded shares of Amicus Therapeutics from a hold rating to a buy rating in a research note on Wednesday, December 27th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $18.31.

Shares of Amicus Therapeutics (NASDAQ:FOLD) opened at $15.72 on Wednesday. The firm has a market capitalization of $2,638.69, a P/E ratio of -8.59 and a beta of 1.72. The company has a current ratio of 6.32, a quick ratio of 6.22 and a debt-to-equity ratio of 0.39. Amicus Therapeutics has a twelve month low of $5.07 and a twelve month high of $16.60.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). The business had revenue of $10.90 million for the quarter, compared to the consensus estimate of $9.02 million. Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The business’s quarterly revenue was up 419.0% on a year-over-year basis. During the same period last year, the firm posted ($0.33) EPS. sell-side analysts forecast that Amicus Therapeutics will post -1.56 EPS for the current year.

In related news, SVP Daphne Quimi sold 8,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $14.72, for a total transaction of $117,760.00. Following the transaction, the senior vice president now owns 62,676 shares in the company, valued at $922,590.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jay Barth sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $14.71, for a total transaction of $73,550.00. Following the transaction, the insider now owns 69,184 shares in the company, valued at approximately $1,017,696.64. The disclosure for this sale can be found here. Insiders have sold 718,920 shares of company stock worth $10,263,669 in the last quarter. Company insiders own 3.40% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of FOLD. Strs Ohio acquired a new position in Amicus Therapeutics in the third quarter worth approximately $102,000. Birchview Capital LP acquired a new position in Amicus Therapeutics in the third quarter worth approximately $151,000. Sage Capital Advisors llc acquired a new position in Amicus Therapeutics in the third quarter worth approximately $154,000. Engineers Gate Manager LP acquired a new position in Amicus Therapeutics in the third quarter worth approximately $155,000. Finally, Tudor Investment Corp ET AL acquired a new position in Amicus Therapeutics in the second quarter worth approximately $124,000.

ILLEGAL ACTIVITY WARNING: “Amicus Therapeutics (FOLD) Rating Reiterated by Cowen” was reported by Stock Observer and is the property of of Stock Observer. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://www.thestockobserver.com/2018/01/13/amicus-therapeutics-fold-rating-reiterated-by-cowen.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply